Mads Krogsgaard Thomsen, CEO of Novo Nordisk Foundation, discusses European competitiveness.

By Nikhil Sharma and Pranav Kashyap (Reuters) -European shares rose on Tuesday, buoyed by gains in the healthcare and luxury ...

(Reuters) - European shares were subdued on Tuesday, as rising financials and healthcare shares countered broader losses ...

European shares held steady with slight gains in financials and healthcare despite global uncertainties over U.S. President Donald Trump's proposed tariffs. The market's cautious optimism was ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China — as he has increasingly ...

With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

If successful in later stage trials, the company will be entering into a market space currently dominated by Novo Nordisk’s Weygovy and Eli Lilly’s Zepbound with the new entrant having the significant ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...